Anticancer agent 304

Anticancer agent 304 是一种抗癌剂,可与 CDC45 结合(Kd 为 83.0 μM),将肝癌细胞周期阻滞于 G2/M 期,通过上调 C-PARP-1、下调 PARP-1 和 BCL-2 诱导细胞凋亡 (Apoptosis),并抑制肝癌细胞的迁移、侵袭和增殖,同时在肝细胞癌动物模型中可抑制肿瘤生长,可用于肝癌的相关研究。
产品编号: MS-F30276 CAS No.: 3115940-07-0 分子式: C42H46O8 分子量: 678.81
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Anticancer agent 304 是一种抗癌剂,可与 CDC45 结合(Kd 为 83.0 μM),将肝癌细胞周期阻滞于 G2/M 期,通过上调 C-PARP-1、下调 PARP-1 和 BCL-2 诱导细胞凋亡 (Apoptosis),并抑制肝癌细胞的迁移、侵袭和增殖,同时在肝细胞癌动物模型中可抑制肿瘤生长,可用于肝癌的相关研究。

生物实验数据

生物活性 Anticancer agent 304 is an anticancer agent that binds to CDC45 with a Kd of 83.0 μM, induces G2/M phase cell cycle arrest in liver cancer cells, triggers apoptosis by upregulating C-PARP-1 and downregulating PARP-1 and BCL-2, inhibits the migration, invasion, and proliferation of liver cancer cells, suppresses tumor growth in hepatocellular carcinoma animal models, and can be used for research related to liver cancer.
体外研究
(In Vitro)

Anticancer agent 304 (Compound 17) 可强效抑制 HepG2、Huh-7 和 SK-Hep-1 细胞的增殖,IC50 值分别为 1.5 μM、1.1 μM 和 1.1 μM。
Anticancer agent 304 (0.5-1.5 μM; 24 h) 可抑制 SK-Hep-1 和 Huh-7 细胞的克隆形成增殖,降低细胞中的 CDC45 蛋白表达水平,促进细胞中 CDC45 的核输出。
Anticancer agent 304 (1.56-250 μM) 可直接与纯化的 CDC45 蛋白结合,Kd 为 83.0 μM。
Anticancer agent 304 (0.5-1.5 μM; 12 h) 可通过上调 p27 并下调 p-CDC2 将 SK-Hep-1 和 Huh-7 细胞阻滞于细胞周期的 G2/M 期。
Anticancer agent 304 (0.5-1.5 μM; 48 h) 可通过上调 C-PARP-1、下调 PARP-1 和 BCL-2,诱导 SK-Hep-1 和 Huh-7 肝癌细胞发生凋亡。
Anticancer agent 304 (0.5-1.5 μM; 48 h) 可通过上调 E-cadherin、下调 N-cadherin 和 Vimentin 来逆转上皮间质转化,抑制 SK-Hep-1 和 Huh-7 肝癌细胞的迁移与侵袭。

Cell Proliferation Assay

Cell Line: Huh-7, SK-Hep-1 hepatocellular carcinoma cell lines
Concentration: 0 μM, 0.5 μM, 1.0 μM, 1.5 μM
Incubation Time: 24 h (initial treatment)
Result: Inhibited colony formation by 34.0% (0.5 μM), 72.9% (1.0 μM), and 97.6% (1.5 μM) in SK-Hep-1 cells.
Inhibited colony formation by 41.0% (0.5 μM), 64.7% (1.0 μM), and 89.1% (1.5 μM) in Huh-7 cells.

Western Blot Analysis

Cell Line: Huh-7, SK-Hep-1 hepatocellular carcinoma cell lines
Concentration: 0 μM, 0.5 μM, 1.0 μM, 1.5 μM
Incubation Time: 24 h
Result: Significantly decreased CDC45 protein levels in both Huh-7 and SK-Hep-1 cells.

Cell Cycle Analysis

Cell Line: Huh-7, SK-Hep-1 hepatocellular carcinoma cell lines
Concentration: 0 μM, 0.5 μM, 1.0 μM, 1.5 μM
Incubation Time: 12 h
Result: Arrested the cell cycle at the G2/M phase: in SK-Hep-1 cells, the percentage of G2/M phase cells increased from 23.5% to 27.1% (0.5 μM), 41.1% (1.0 μM), and 63.5% (1.5 μM); in Huh-7 cells, the percentage increased from 21.6% to 25.9% (0.5 μM), 28.2% (1.0 μM), and 34.8% (1.5 μM).
Upregulated p27 and downregulated p-CDC2 in both cell lines.

Immunofluorescence

Cell Line: Huh-7, SK-Hep-1 hepatocellular carcinoma cell lines
Concentration: 0 μM, 0.5 μM, 1.0 μM, 1.5 μM
Incubation Time: 24 h
Result: Induced nuclear export of CDC45, decreasing nuclear localization and increasing cytoplasmic accumulation in both cell lines.

Apoptosis Analysis

Cell Line: Huh-7, SK-Hep-1 hepatocellular carcinoma cell lines
Concentration: 0 μM, 0.5 μM, 1.0 μM, 1.5 μM
Incubation Time: 48 h
Result: Significantly induced apoptosis: in Huh-7 cells, the proportion of apoptotic cells increased from 4.8% to 14.4% (0.5 μM), 38.5% (1.0 μM), and 72.2% (1.5 μM); in SK-Hep-1 cells, the proportion increased from 2.1% to 28.7% (0.5 μM), 65.5% (1.0 μM), and 84.0% (1.5 μM).
Upregulated C-PARP-1 and downregulated PARP-1 and BCL-2 in both cell lines.
体内研究
(In Vivo)

Anticancer agent 304 (30-60 mg/kg; i.p.; every day; 51 days) 在肝细胞癌异种移植裸鼠中展现出高效且无毒的抗肝癌活性,在 30 mg/kg 和 60 mg/kg 剂量下分别实现 76%和 84%的肿瘤重量抑制率,同时可降低肿瘤组织中 CDC45 的表达。

Animal Model: NU/NU nude mice (male, 4 weeks old, subcutaneously injected with Huh-7 cells)
Dosage: 30 mg/kg; 60 mg/kg
Administration: i.p.; every day; 51 days
Result: Inhibited tumor growth by 73% at 30 mg/kg after 51 days.
Reduced tumor weight by 76% at 30 mg/kg after 51 days.
Inhibited tumor growth by 84% at 60 mg/kg after 51 days.
Reduced tumor weight by 84% at 60 mg/kg after 51 days.
Reduced CDC45 protein expression in tumor tissues compared to controls.
Caused no compound-related body weight alterations.
Maintained serum levels of hepatic/renal biomarkers (ALT/GPT, AST/GOT, BUN, CRE) within normal ranges.
Showed no structural abnormalities in major organs (heart, liver, spleen, lung, kidney) via histopathological analysis.

化学信息

分子量 678.81
分子式 C42H46O8
CAS No. 3115940-07-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础